Diabetes care - Hrudoy 2019

20 Questions | Total Attempts: 116

SettingsSettingsSettings
Diabetes care - Hrudoy 2019 - Quiz

ONLINE QUIZ DIABETES CARE - HRUDOY 2019


Questions and Answers
  • 1. 
    The United Kingdom Prospective Diabetes Study (UKPDS) showed that intensive therapy (mean A1C value of 7%) with OHAs or insulin resulted in a decreased risk of microvascular complications compared with conventional therapy with diet (mean A1C value of 7.9%) at the end of the study 1997. According to UKPDS 0.9% reduction in A1C at 10 years was associated with a ___ reduction in microvascular endpoints.
    • A. 

      5%

    • B. 

      15%

    • C. 

      25%

    • D. 

      35%

  • 2. 
    According to a meta-analysis of intensive glucose-lowering trials, the benefit of different interventions with 5 year treatment, which of the following results in better reduction of CV events?
    • A. 

      Reduction of systolic BP (4 mmHg)

    • B. 

      Reduction of HbA1C (0.9%)

    • C. 

      Reduction of LDL cholesterol (38.6 mg/dL)

    • D. 

      All of the above

  • 3. 
    In elderly long-standing diabetes with comorbidities the HBA1C goal is
    • A. 

      6-6.5%

    • B. 

      6.5-7%

    • C. 

      7-7.5%

    • D. 

      7.5-8%

  • 4. 
    According to East-West Study
    • A. 

      Patients with DM but no CHD experience a higher rate of MI as patients without DM but with CHD

    • B. 

      Patients with DM but no CHD experience a lower rate of MI as patients without DM but with CHD2

    • C. 

      Patients with DM but no CHD experience a similar rate of MI as patients without DM but with CHD

  • 5. 
    According to ADA guidelines diagnostic criteria for diabetes by HbA1C
    • A. 

      Diabetes is diagnosed if HbA1c ≥ 6% in at least 2 measurements

    • B. 

      Diabetes is diagnosed if HbA1c ≥ 6.5% in at least 2 measurements

    • C. 

      Diabetes is diagnosed if HbA1c ≥ 7% in at least 2 measurements

    • D. 

      Diabetes is diagnosed if HbA1c ≥ 7.5% in at least 2 measurements

  • 6. 
    A 50 year old man with history of myocardial infarction has new onset type 2 diabetes with HbA1C 8%. You are considering drug treatment, the first drug to be considered is
    • A. 

      Metformin

    • B. 

      Gliptins

    • C. 

      SGLT2 inhibitor

    • D. 

      GLP-1 agonists

  • 7. 
    According to ADA all of the following are the criteria for the diagnosis of diabetes except
    • A. 

      FPG ≥ 110 mg/dL

    • B. 

      HbA1C ≥ 6.5%

    • C. 

      2-h PG ≥ 200 mg/dL

    • D. 

      Classical symptoms of hyperglycemia and random PG ≥ 200 mg/dL

  • 8. 
    According to ADA guidelines the following combination of drugs is not recommended in the treatment of T2D
    • A. 

      DPP-4 inhibitors and GLP-1 agonists

    • B. 

      GLP-1 agonists and SGLT2 inhibitors

    • C. 

      SGLT2 inhibitors and TZDs

    • D. 

      DPP-4 inhibitors and TZDs

  • 9. 
    The following drugs have shown cardiovascular benefits by decreasing MACE
    • A. 

      Metformin and insulin

    • B. 

      DPP4 inhibitors and Metformin

    • C. 

      SGLT2 inhibitors and GLP-1 agonists

    • D. 

      SGLT2 inhibitors and long acting GLP-1 agonists

  • 10. 
    The following drugs are not to be used in T2D patients with CHF
    • A. 

      GLP1 agonists and SGLT2i

    • B. 

      α-glucosidase inhibitors and Linagliptin

    • C. 

      Linagliptin and Dapagliflozin

    • D. 

      TZDs and Saxagliptin

  • 11. 
    The impact of hypoglycemia in patients with diabetes has been well documented. Which of the following statements is true?
    • A. 

      Incidence of hypoglycemia is correlated with increased adherence to antihyperglycemic medications

    • B. 

      Hypoglycemic episodes are associated with reduced health-related quality of life

    • C. 

      Patients who have hypoglycemic episodes are more likely to be at glycemic targets

    • D. 

      There is no correlation between hypoglycemia and death

  • 12. 
    Hypoglycemia is more common with the following drug/drugs
    • A. 

      Dapagliflozin

    • B. 

      Linagliptin

    • C. 

      Glimepride

    • D. 

      2&3

    • E. 

      All of the above

  • 13. 
    Which of the following drugs has shown significant cardiovascular benefit in T2D with high CVD risk
    • A. 

      Empagliflozin

    • B. 

      Dapagliflozin

    • C. 

      Sitagliptin

    • D. 

      Insulin

  • 14. 
    Which of the following drugs can be used in patients with CKD (eGFR < 30ml/min)
    • A. 

      Metformin

    • B. 

      Glibenclamide

    • C. 

      Linagliptin

    • D. 

      Empagliflozin

  • 15. 
    Testing for diabetes in asymptomatic individuals should be considered in overweight or obese who have one or more of the following risk factors except
    • A. 

      First-degree relative with diabetes

    • B. 

      Hypertension (≥140/90 mmHg or therapy for hypertension)

    • C. 

      Active smoker

    • D. 

      Women with polycystic ovary syndrome

  • 16. 
    Which of the following drug/drugs on long term treatment requires least number of patients to prevent one CV death (NNT) in T2D?
    • A. 

      Statins

    • B. 

      Antihypertensives

    • C. 

      Aspirin

    • D. 

      Empagliflozin

  • 17. 
    Fournier’s gangrene (acute perineal necrotizing fasciitis) is a serious complication of drug treatment of T2D. Which drug/drug class has been associated with this complication?
    • A. 

      Saxagliptin

    • B. 

      SGLT2i

    • C. 

      GLP-1 agonists

    • D. 

      Rosiglitazone

  • 18. 
    Multiple gas containing cysts in the sub mucosal or subserosal layer of intestine (Pneumatosis) It may be associated with range of GI conditions such as bowel gangrene to inflammatory bowel disease and rarely with mechanical ventilation and endoscopic procedures. Which antidiabetic drug is associated with this rare condition?
    • A. 

      Rosiglitazone

    • B. 

      Dapagliflozin

    • C. 

      Saxagliptin

    • D. 

      Acarbose

  • 19. 
    The following class of drugs acts by stimulating the pancreas to produce more insulin
    • A. 

      Sulfonylureas

    • B. 

      Meglitinides

    • C. 

      Gliptins

    • D. 

      A and b

    • E. 

      A and c

  • 20. 
    The following oral hypoglycemic agent raised serious concern about cardiovascular safety resulting in FDA guidance to industry to evaluate CV risk in new therapies to treat T2D in 2008.
    • A. 

      Saxagliptin

    • B. 

      Rosiglitazone

    • C. 

      Repaglinide

    • D. 

      Exenatide

Back to Top Back to top